{"elems":[{"type":"t","desc":"Empiric antibiotic regimens. Normal renal function"},{"type":"t","desc":"In non critically ill patients:"},{"type":"e","desc":"Amoxicillin\/clavulanate 1.2-2.2 g; 8-hourly"},{"type":"e","desc":"or"},{"type":"e","desc":"Ceftriaxone 2 g; 24-hourly + Metronidazole 500 mg; 6-hourly"},{"type":"e","desc":"or"},{"type":"e","desc":"Piperacillin\/Tazobactam 4.5 g; 6-hourly (critically ill patients)"},{"type":"d"},{"type":"t","desc":"In patients with beta-lactam allergy:"},{"type":"e","desc":"Ciprofloxacin 400 mg; 8\/12-hourly + Metronidazole 500 mg; 6- hourly"},{"type":"d"},{"type":"t","desc":"In patients at high risk for community-acquired ESBL-producing Enterobacteriaceae infections:"},{"type":"e","desc":"Tigecycline 100 mg LD, then 50 mg 12-hourly (Carbapenem-sparing strategy)"},{"type":"e","desc":"or"},{"type":"e","desc":"Ertapenem 1 g; 24-hourly"},{"type":"e","desc":"or"},{"type":"e","desc":"Meropenem 1 g; 8-hourly (only in patients with septic shock)"},{"type":"e","desc":"or"},{"type":"e","desc":"Doripenem 500 mg; 8-hourly (only in patients with septic shock)"},{"type":"e","desc":"or"},{"type":"e","desc":"Imipenem\/Cilastatin 500 mg; 6-hourly (only in patients with septic shock)"},{"type":"t","desc":"In patients at high risk for infection with Enterococci including immunocompromised patients or patients with recent antibiotic exposure"},{"type":"e","desc":"Ampicillin 2 g; 6-hourly if the patients are not being treated with Piperacillin\/Tazobactam or Imipenem\/Cilastatin (active against ampicillin-susceptible enterococci) or Tigecycline"}]}